{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.33","upperLimit":"48.08","value":"4.00"},{"groupId":"OG001","lowerLimit":"6.00","upperLimit":"6.00","value":"6.00"},{"groupId":"OG002","lowerLimit":"2.17","upperLimit":"49.33","value":"4.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Single oral dose of bosutinib 400 mg on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study.","id":"OG000","title":"Bosutinib 400 mg (Part 1)"},{"description":"Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study.","id":"OG001","title":"Bosutinib 500 mg (Part 1)"},{"description":"Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in AP-CML Part 2 of the study.","id":"OG002","title":"Bosutinib 600 mg (Part 1)"}],"paramType":"MEDIAN","populationDescription":"Evaluable population included all enrolled participants who received at least one dose of study medication and had an adequate baseline efficacy assessment.","reportingStatus":"POSTED","timeFrame":"0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1","title":"Time to Reach Maximum Observed Plasma Concentration (Tmax) - Part 1","type":"PRIMARY","unitOfMeasure":"hours (hrs)"}